Ekso Bionics Holdings analyst ratings
Ekso Bionics Holdings analyst ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
07/29/2022 | 420.23% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
10/30/2020 | 535.84% | HC Wainwright & Co. | $12 → $11 | Maintains | Buy |
08/03/2020 | 420.23% | Aegis Capital | $13 → $9 | Maintains | Buy |
06/26/2020 | 593.64% | HC Wainwright & Co. | $8 → $12 | Maintains | Buy |
06/15/2020 | 362.43% | HC Wainwright & Co. | $1.2 → $8 | Maintains | Buy |
05/21/2020 | 651.45% | Aegis Capital | $15 → $13 | Maintains | Buy |
04/13/2020 | 767.05% | Aegis Capital | $21.75 → $15 | Maintains | Buy |
03/25/2020 | 362.43% | Cantor Fitzgerald | $1 → $8 | Maintains | Overweight |
10/28/2019 | -30.64% | HC Wainwright & Co. | → $1.2 | Initiates Coverage On | → Buy |
09/06/2019 | -42.2% | Cantor Fitzgerald | → $1 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
07/29/2022 | 420.23% | HC Wainwright & Co. | 11 美元 → 9 美元 | 维护 | 买 |
10/30/2020 | 535.84% | HC Wainwright & Co. | 12 美元 → 11 美元 | 维护 | 买 |
2020 年 3 月 8 日 | 420.23% | 宙斯盾资本 | 13 美元 → 9 美元 | 维护 | 买 |
06/26/2020 | 593.64% | HC Wainwright & Co. | 8 美元 → 12 美元 | 维护 | 买 |
06/15/2020 | 362.43% | HC Wainwright & Co. | 1.2 美元 → 8 美元 | 维护 | 买 |
05/21/2020 | 651.45% | 宙斯盾资本 | 15 美元 → 13 美元 | 维护 | 买 |
2020 年 4 月 13 日 | 767.05% | 宙斯盾资本 | 21.75 美元 → 15 美元 | 维护 | 买 |
2020 年 3 月 25 日 | 362.43% | 坎托·菲茨杰拉德 | $1 → 8 美元 | 维护 | 超重 |
2019 年 10 月 28 日 | -30.64% | HC Wainwright & Co. | → 1.2 美元 | 启动覆盖范围开启 | → 购买 |
09/06/2019 | -42.2% | 坎托·菲茨杰拉德 | → 1 美元 | 启动覆盖范围开启 | → 超重 |
Ekso Bionics Holdings Questions & Answers
Ekso Bionics Holdings 问答
The latest price target for Ekso Bionics Holdings (NASDAQ: EKSO) was reported by HC Wainwright & Co. on July 29, 2022. The analyst firm set a price target for $9.00 expecting EKSO to rise to within 12 months (a possible 420.23% upside). 1 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年7月29日公布了埃克索仿生控股公司(纳斯达克股票代码:EKSO)的最新目标股价。该分析公司将目标股价定为9.00美元,预计EKSO将在12个月内升至12个月内(可能上涨420.23%)。1家分析公司去年公布了评级。
The latest analyst rating for Ekso Bionics Holdings (NASDAQ: EKSO) was provided by HC Wainwright & Co., and Ekso Bionics Holdings maintained their buy rating.
埃克索仿生控股公司(纳斯达克股票代码:EKSO)的最新分析师评级由HC Wainwright & Co. 提供,Ekso Bionics Holdings维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ekso Bionics Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ekso Bionics Holdings was filed on July 29, 2022 so you should expect the next rating to be made available sometime around July 29, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Ekso Bionics Holdings的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Ekso Bionics Holdings的最新评级是在2022年7月29日公布的,因此您应该预计下一个评级将在2023年7月29日左右公布。
While ratings are subjective and will change, the latest Ekso Bionics Holdings (EKSO) rating was a maintained with a price target of $11.00 to $9.00. The current price Ekso Bionics Holdings (EKSO) is trading at is $1.73, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Ekso Bionics Holdings(EKSO)评级维持不变,目标股价为11.00美元至9.00美元。Ekso Bionics Holdings(EKSO)目前的交易价格为1.73美元,超出了分析师的预期区间。